India Drug-Pricing Authority To Give Pharmas Incentives To Improve Products (India)
This article was originally published in PharmAsia News
India's National Pharmaceutical Pricing Authority plans a new system that would require drug makers to undergo more scrutiny on whether new ingredients and packaging materials improve the quality of their drug. The changes are intended to give pharmas incentives to make those changes because they then would be able to charge a higher price for their product if the changes improve quality. Drug makers have said the price controls placed on them in India kept the companies from making changes to extend the shelf life of their drugs and enhance their qualities. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.